Skip to main content

Table 2 Top 20 reported adverse events among patients prescribed artesunate–amodiaquine during follow-up contact by phone and home visit

From: Feasibility and cost of using mobile phones for capturing drug safety information in peri-urban settlement in Ghana: a prospective cohort study of patients with uncomplicated malaria

Adverse eventsa

Phone

n, % (95 % CI)

Home

n, % (95 % CI)

Total

n, % (95 % CI)

Drowsiness

225, 26.2 (23.3–29.3)

227, 31.1 (27.8–34.6)

452, 28.4 (26.2–30.7)

Dizziness

100, 11.6 (9.6–14.0)

80, 11.0 (8.8–13.5)

180, 11.3 (9.8–13.0)

General weakness

93, 10.8 (8.8–13.1)

57, 7.8 (6.0–10.0)

150, 9.4 (8.0–11.0)

Vomiting

67, 7.8 (6.1–9.8)

86, 11.8 (9.5–14.3)

153, 9.6 (8.2–11.2)

Loss of appetite

41, 4.8 (3.4–6.4)

14, 1.9 (1.1–3.2)

55, 3.5 (2.6–4.5)

Stomach ache

38, 4.4 (3.1–6.0)

30, 4.1 (2.8–5.8)

68, 4.3 (3.3–5.4)

Fever

38, 4.4 (3.1–6.0)

20, 2.7 (1.7–4.2)

58, 3.7 (2.8–4.7)

Headache

29, 3.4 (2.3–4.8)

20, 2.7 (1.7–4.2)

49, 3.1 (2.3–4.1)

Cough

29, 3.4 (2.3–4.8)

15, 2.1 (1.1–3.4)

44, 2.8 (2.0–3.7)

Diarrhoea

23, 2.7 (1.7–4.0)

20, 2.7 (1.7–4.2)

43, 2.7 (2.0–3.6)

Nausea

19, 2.2 (1.3–3.4)

33, 4.5 (3.1–6.3)

52, 3.3 (2.5–4.3)

Palpitation

17, 2.0 (1.1–3.1)

22, 3.0 (1.9–4.5)

39, 2.5 (1.8–3.3)

Chills

12, 1.4 (0.7–2.4)

6, 0.8 (0.3–1.8)

18, 1.1 (0.7–1.8)

Restlessness

10, 1.2 (0.6–2.1)

7, 1.0 (0.3–2.0)

17, 1.1 (0.6–1.7)

Body pain

9, 1.0 (0.5–2.0)

7, 1.0 (0.3–2.0)

16, 1.0 (0.5–1.6)

Sleeplessness

9, 1.0 (0.5–2.0)

6, 0.8 (0.3–1.8)

15, 0.9 (0.5–1.6)

Body itchiness

8, 0.9 (0.4–1.8)

10, 1.4 (0.7–2.5)

18, 1.1 (0.6–1.8)

Sore mouth

7, 0.8 (0.3–1.7)

4, 0.5 (0.1–1.4)

11, 0.7 (0.3–1.2)

Cold

7, 0.8 (0.3–1.7)

2, 0.3 (0.1–1.4)

9, 0.6 (0.2–1.1)

Skin rashes

7, 0.8 (0.3–1.7)

1, 0.1 (0.0–0.7)

8, 0.5 (0.2–1.0)

  1. aOne patient could report more than one adverse event